Antimetabolites: Purine and Pyrimidine Analogs

Purine and pyrimidine antimetabolites are anticancer drugs built to resemble the natural bases and nucleosides of DNA and RNA. By imitating these building blocks, they inhibit the enzymes of nucleotide synthesis or are incorporated into nucleic acids as defective substrates, halting cell division. They are classic S-phase-active agents, exerting their greatest effect on cells actively synthesizing DNA.

Definition

Purine and pyrimidine antimetabolites are structural analogs of the natural nucleobases or nucleosides that competitively inhibit enzymes in nucleotide biosynthesis or are misincorporated into DNA or RNA, thereby disrupting nucleic-acid synthesis and function.

Scope

This entry covers the two main families of nucleobase antimetabolites, pyrimidine analogs and purine analogs, their general mechanisms of competitive inhibition and fraudulent incorporation, and their characteristic cell-cycle dependence. It is a pharmacology reference topic and does not address dosing, selection, or administration of specific drugs.

Core questions

• How does a base or nucleoside analog interfere with nucleic-acid synthesis?
• What distinguishes pyrimidine analogs from purine analogs mechanistically?
• Why are these agents most active during S phase?
• How does fraudulent incorporation into DNA or RNA cause cytotoxicity?
• What general mechanisms underlie resistance to antimetabolites?

Key concepts

• Competitive enzyme inhibition
• Fraudulent incorporation into DNA or RNA
• Pyrimidine analogs
• Purine analogs
• Thymidylate synthase inhibition
• S-phase specificity
• Pro-drug activation

Mechanisms

Antimetabolites work by impersonating physiologic metabolites. Pyrimidine analogs such as fluoropyrimidines are converted intracellularly into active nucleotides that inhibit thymidylate synthase, depriving the cell of thymidylate needed for DNA synthesis, and can also be incorporated into RNA and DNA to disrupt their function. Purine analogs are likewise activated to nucleotides that inhibit purine biosynthesis or are incorporated into nucleic acids as faulty substrates. Because these effects converge on DNA replication, the agents are most lethal to cells in S phase, making them cell-cycle specific. Cytotoxicity follows from both the depletion of essential nucleotides and the structural corruption of newly made DNA and RNA. Resistance can develop through altered drug activation or catabolism, changes in target-enzyme levels, and expanded nucleotide pools that dilute the analog (Longley et al., 2003; Goodman & Gilman, 2018).

Clinical relevance

Antimetabolites are mainstays of treatment for a range of solid tumours and leukemias and feature in many combination regimens, and their S-phase dependence informs how schedules are conceived. This topic explains the pharmacologic mechanism of the class for educational appraisal and does not constitute treatment guidance.

Evidence & guidelines

The mechanisms of nucleobase antimetabolites are well-characterized textbook pharmacology, detailed in references such as Goodman & Gilman and in focused mechanistic reviews. The fluoropyrimidine review by Longley and colleagues is a widely cited account of how a pyrimidine analog inhibits thymidylate synthase and is incorporated into nucleic acids (Longley et al., 2003; Chabner & Roberts, 2005).

History

Antimetabolite chemotherapy began with the recognition in the mid-twentieth century that analogs of natural metabolites could starve dividing cells of essential building blocks. Purine analogs developed by George Hitchings and Gertrude Elion and the later design of fluoropyrimidines extended the strategy across leukemias and solid tumours, establishing the class alongside the alkylating agents as a pillar of cytotoxic therapy (Chabner & Roberts, 2005).

Key figures

• Bruce Chabner

Seminal works

• longley-2003
• chabner-roberts-2005

Frequently asked questions

Why are antimetabolites most effective against cells in S phase?

Because they disrupt the synthesis or fidelity of DNA, they have their greatest effect when the cell is actively replicating its DNA during S phase, which makes them cell-cycle-specific agents.

What does fraudulent incorporation mean?

It refers to an analog being mistaken for a normal base or nucleotide and built into DNA or RNA, where its abnormal structure disrupts the function and stability of the nucleic acid.